Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Muromonab (OKT-3) with Low-Dose Cyclophosphamide in Advanced Malignancies
NCT00002482Phase 2Unknown
- Sponsor
- St. Vincent Medical Center
- Start
- Jun 1991
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of muromonab-CD3 in metastatic cancer, brain tumor, sponsored by St. Vincent Medical Center. Status: unknown.
02
Drugs
muromonab-CD3
03
Conditions
metastatic cancerbrain tumor
Beyond the preview
Go deeper on NCT00002482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002482.